InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,187.28
(
0.13%
)
US TECH 100
17,607.20
(
-0.02%
)
Dow Jones
38,896.14
(
0.11%
)
Brent Oil
83.11
(
-0.44%
)
Bitcoin
63,128.37
(
-0.06%
)
Post# of 251747
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 828
Posts 119586
Boards Moderated 14
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 165226

Monday, 11/25/2013 8:45:55 AM

Monday, November 25, 2013 8:45:55 AM

Post# of 251747
ENTA’s cash balance at 9/30/12 was $112.2M; cash usage using during FY4Q13 was only $2.6M:

http://finance.yahoo.com/news/enanta-pharmaceuticals-reports-financial-results-123000980.html

Given the $195M in pre-commercial milestones expected from ABBV for regulatory filing ($40M in calendar 2Q14) and regulatory approval ($150M expected in early calendar 2015) of ABBV’s 3-DAA HCV regimen (#msg-91918990), it’s clear that ENTA does not have a liquidity probem.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up